![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![Renejix CDMO Partner for Small Molecule Oral Dosage Forms](https://www.pharmacompass.com/image/flap/renejix-w35-desktop-header-01gif-33629.gif)
![Renejix CDMO Partner for Small Molecule Oral Dosage Forms](https://www.pharmacompass.com/image/flap/renejix-w35-mob-header-01gif-17728.gif)
X
20
Calao S.r.l. Milano It, based in U.S.A, is a pharmaceutical company.
One of their significant offerings is Glibenclamide, supported by a 'Withdrawn by Holder' Certificate of Suitability (CEP) with the number R0-CEP 2001-361 - Rev 02
This Chemical Type CEP, issued on October 05, 2006, remains in force until June 15, 2008, ensuring its reliability within the pharmaceutical industry.
Substance Number 718 associated with this CEP further emphasizes